|
SK285141B6
(sk)
|
1996-02-13 |
2006-07-07 |
Astrazeneca Uk Limited |
Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
|
|
ATE211134T1
(de)
|
1996-03-05 |
2002-01-15 |
|
4-anilinochinazolin derivate
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
|
ATE368665T1
(de)
|
1997-08-22 |
2007-08-15 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
US6399743B1
(en)
|
1999-05-14 |
2002-06-04 |
Dept. Of Veterans Affairs |
Isolation and characterization of a rat epidermal growth factor related protein
|
|
US7049410B2
(en)
*
|
1999-05-14 |
2006-05-23 |
Majumdar Adhip P N |
Antibodies to a novel EGF-receptor related protein (ERRP)
|
|
HU229414B1
(hu)
|
1999-11-05 |
2013-12-30 |
Astrazeneca Ab |
Kinazolin-származékok mint VEGF-inhibitorok, eljárás az elõállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
|
|
US6638929B2
(en)
|
1999-12-29 |
2003-10-28 |
Wyeth |
Tricyclic protein kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
CN1240688C
(zh)
|
2000-04-07 |
2006-02-08 |
阿斯特拉曾尼卡有限公司 |
喹唑啉化合物
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
US7115615B2
(en)
|
2000-08-21 |
2006-10-03 |
Astrazeneca |
Quinazoline derivatives
|
|
EP1326860A1
(en)
*
|
2000-10-13 |
2003-07-16 |
AstraZeneca AB |
Quinazoline derivatives
|
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
JP2005526714A
(ja)
*
|
2002-01-17 |
2005-09-08 |
ニューロジェン・コーポレーション |
カプサイシンのモジュレーターとしての置換キナゾリン−４−イルアミン類縁体
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
AU2003300898A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Neurogen Corporation |
Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
TW200510373A
(en)
*
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
|
SI1667991T1
(sl)
|
2003-09-16 |
2008-10-31 |
Astrazeneca Ab |
Kinazolinski derivati kot inhibitorji tirozin kinaze
|
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
KR20080095915A
(ko)
|
2004-05-06 |
2008-10-29 |
워너-램버트 캄파니 엘엘씨 |
4-페닐아미노-퀴나졸린-6-일-아미드
|
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
|
ATE501148T1
(de)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
JP5377332B2
(ja)
|
2007-02-06 |
2013-12-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
|
|
BRPI0907916A2
(pt)
|
2008-02-07 |
2015-07-28 |
Boehringer Ingelheim Int |
Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
|
|
AU2009247782C1
(en)
|
2008-05-13 |
2013-09-19 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
|
|
US8648191B2
(en)
|
2008-08-08 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
EP2349235A1
(en)
|
2008-11-07 |
2011-08-03 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012520893A
(ja)
|
2009-03-18 |
2012-09-10 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
|
|
CA2780875A1
(en)
|
2009-11-13 |
2011-05-19 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
CA2845179A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
|
EP2761025A1
(en)
|
2011-09-30 |
2014-08-06 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
EP2961412A4
(en)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
CANCER THERAPY
|
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
JP6900314B2
(ja)
|
2014-12-24 |
2021-07-07 |
ジェネンテック， インコーポレイテッド |
膀胱癌の治療、診断、及び予後判定方法
|
|
SG11201906223TA
(en)
|
2016-12-22 |
2019-08-27 |
Amgen Inc |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
EP4403175A3
(en)
|
2017-09-08 |
2024-10-02 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
JP7361722B2
(ja)
|
2018-05-04 |
2023-10-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
|
|
CA3099045A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
MX2020012731A
(es)
|
2018-06-01 |
2021-02-22 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
|
EP3860608A1
(en)
|
2018-10-04 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MX2021007104A
(es)
|
2018-12-20 |
2021-08-11 |
Amgen Inc |
Inhibidores de kif18a.
|
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
TWI844602B
(zh)
|
2018-12-20 |
2024-06-11 |
美商安進公司 |
Kif18a抑制劑
|
|
US12441705B2
(en)
|
2018-12-20 |
2025-10-14 |
Amgen Inc. |
KIF18A inhibitors
|
|
JP2022522777A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロアリール化合物及びその使用
|
|
AU2020232616A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
CN118834208A
(zh)
|
2019-05-21 |
2024-10-25 |
美国安进公司 |
固态形式
|
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
MX2022001296A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
|
ES3051917T3
(en)
|
2019-08-02 |
2025-12-30 |
Amgen Inc |
Kif18a inhibitors
|
|
EP4048671A1
(en)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
CN114867735A
(zh)
|
2019-11-04 |
2022-08-05 |
锐新医药公司 |
Ras抑制剂
|
|
MX2022005357A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ｒａｓ阻害剤
|
|
KR20220100903A
(ko)
|
2019-11-08 |
2022-07-18 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
|
CN114728960B
(zh)
|
2019-11-14 |
2025-05-27 |
美国安进公司 |
Kras g12c抑制剂化合物的改善的合成
|
|
EP4058432A1
(en)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
TW202140011A
(zh)
|
2020-01-07 |
2021-11-01 |
美商銳新醫藥公司 |
Shp2抑制劑給藥和治療癌症的方法
|
|
BR112022025550A2
(pt)
|
2020-06-18 |
2023-03-07 |
Revolution Medicines Inc |
Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
|
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
|
TW202227460A
(zh)
|
2020-09-15 |
2022-07-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
TW202241885A
(zh)
|
2020-12-22 |
2022-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Ｓｏｓ１抑制劑及其用途
|
|
US12252497B2
(en)
|
2021-05-05 |
2025-03-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ｒａｓ阻害剤及びその使用
|
|
MX2023013085A
(es)
|
2021-05-05 |
2023-11-16 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
MX2024010828A
(es)
|
2022-03-07 |
2024-09-17 |
Amgen Inc |
Procedimiento para preparar 4-metil-2-propan-2-il-piridin-3-carbon itrilo.
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
AU2023285116A1
(en)
|
2022-06-10 |
2024-12-19 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CR20250141A
(es)
|
2022-10-14 |
2025-05-26 |
Black Diamond Therapeutics Inc |
Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
|
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
WO2024216016A1
(en)
|
2023-04-14 |
2024-10-17 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
TW202448897A
(zh)
|
2023-04-14 |
2024-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|